张蕾，博士生导师，现任中国科学院福建物质结构研究所研究员。主要从事生物分子靶向纳米运载体的研发、肿瘤多药耐药性（MDR）的机制及靶向MDR肿瘤纳米药物研究。成果包括：通过CRISPR/Cas9 基因敲除证明了磷酸肌醇三激酶 PI3K 110α/110β、周期蛋白依赖性激酶CDK6为逆转肿瘤多药耐药性的潜在靶点、PI3K-CDK6为逆转P-糖蛋白介导的肿瘤多药耐药性的信号通路轴；设计了具有肿瘤靶向性的多功能纳米体系PBDF，有望克服P-糖蛋白介导的肿瘤多药耐药性；构建了pH敏感的“PMMMA/PLGA/抗原”口服疫苗体系和一系列肿瘤靶向的药物及基因传递体系。在Molecular Cancer、Acta Pharmaceutica Sinica B、Biomaterials等国内外权威刊物上以第一作者和通讯作者发表了多篇学术论文。现为福建省高层次人才（C类），获得武汉大学优秀博士后奖（2010年）、第十五届、第十六届福建省自然科学优秀学术论文一等奖及四项国家发明专利。

1. K. Li, W. Liu*, C. Wu, L. Wang, Y. Huang, Y. Li, H. Zheng, Y. Shang, L. Zhang*, Z. Chen*. The anti-fatigue and sleep-aiding effects vary significantly among different recipes containing Ganoderma lucidum extracts, Heliyon, 2024, 10(10), e30907.

2. L. Zhang*, Y. Li, C. Hu, Y. Chen, Z. Chen, Z.-S. Chen, J.-Y. Zhang*, S. Fang*. CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells, Molecular Cancer, 2022, 21:103.

3. L. Zhang, Y. Li, Q. Wang, Z. Chen*, X. Li, Z. Wu, C. Hu, D. Liao, W. Zhang, Z.-S. Chen*. The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer, Molecular Cancer, 2020, 19:10.

4. L. Zhang, B. Ye, Z. Chen*, Z.-S. Chen*. Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers, Acta Pharmaceutica Sinica B, 2023, 13(3), 982-997.

5. R. Lin, L. Zhang*, B. Ye, Y. Wang, Y.-D. Li, J. Hsu, W. Liu, P. Hu, J. Chen, Z.-S. Chen, Z. Chen*. A multi-functional nano-system combining PI3K-110α/β inhibitor overcomes P-glycoprotein mediated MDR and improves anti-cancer efficiency, Cancer Letters, 2023, 563, 216181.

6. L. Zhang, B. Ye, Y. Lin, Y.-D. Li, J.-Q. Wang, Z.-S. Chen, F.-F. Ping*; Z.-S. Chen*. Ribociclib inhibits P-gp-mediated multidrug resistance in human epidermoid carcinoma cells, Frontiers in Pharmacology, 2022, 13, 867128.

7. C. He, L. Zhang*, W. Liu, Y. Huang, P. Hu, T. Dai, J. Xu*, Z. Chen*. Albumin-based nanoparticles combined with photodynamic therapy enhance the antitumor activity of curcumin derivative C086, Dyes and Pigments, 2021, 189, 109258.

8. L. Zhang, Z. Li, X. Ye*, Z. Chen*. Z.-S. Chen*. Mechanisms of thrombosis and research progress on targeted antithrombotic drugs, Drug Discovery Today, 2021, 26, 10.

9. Y. Lin, Z. Chen*, C. Hu, Z.-S. Chen*, L. Zhang*. Recent progress in antitumor functions of the intracellular antibodies, Drug Discovery Today, 2020, 25, 1109-1120.

10. J. Liu, Z. Chen*, M. Huang, S. Tang, Q. Wang, P. Hu, P. Gupta, C. R. Ashby Jr., Z.-S. Chen*, L. Zhang*. Plasminogen activator inhibitor (PAI) trap3, an exocellular peptide inhibitor of PAI-1, attenuates the rearrangement of F-actin and migration of cancer cells, Experimental Cell Research, 2020, 391, 111987.

11. L. Zhang, C. Hu, W. Yang, X. Liu, Y. Wu*. Chemical synthesis, versatile structures and functions of tailorable adjuvants for optimizing oral vaccination, ACS Applied Materials & Interfaces, 2016, 8(51), 34933-34950.

12. L. Zhang, Z. Zeng, C. Hu, S. L. Bellis, W. Yang, Y. Su, X. Zhang, Y. Wu*. Controlled and targeted release of antigens by intelligent shell for improving applicability of oral vaccines, Biomaterials, 2016, 77(14), 307-319.

13. L. Zhang#, W. Yang#, C. Hu, Q. Wang, Y. Wu*. Properties and applications of nanoparticle/microparticle conveyors with adjuvant characteristics suitable for oral vaccination, International Journal of Nanomedicine, 2018, 13, 2973-2987.

14. L. Zhang*, Y. Fan, Y. Wu*. Using inositol as a biocompatible ligand for efficient transgene expression, International Journal of Nanomedicine, 2015, 10(1), 2871-2884.

15. L. Zhang*, Y. Fan, Y. Wu*. Inositol based non-viral vectors for transgene expression in human cervical carcinoma and hepatoma cell lines, Biomaterials, 2014, 35(6), 2039-2050.